Developing neoantigen cancer vaccines: where are we now?
Nune Markosyan, Robert H Vonderheide · 2026
Read Developing neoantigen cancer vaccines: where are we now? by Nune Markosyan, Robert H Vonderheide (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13562517.txt.
Description
Nune Markosyan and Robert Vonderheide review, in a 2026 paper, where personalized cancer vaccines stand today. Shots against cancer-causing viruses already prevent some cancers. Vaccines meant to treat existing tumors, though, have rarely shrunk them in a meaningful way.
Modern sequencing and computer prediction changed the game. Vaccines can now target neoantigens, the fresh markers thrown up by a tumor's own mutations. Because those markers are tumor-only, the vaccines dodge the tolerance that blunted older designs. Trials show promise, the authors report, while design, delivery, and the best disease stage need refinement. The review maps both the momentum and the homework that remains.
Catalog record
| CREATOR | Nune Markosyan, Robert H Vonderheide |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |